Cookies on this website

We use cookies to ensure that we give you the best experience on our website. If you click 'Accept all cookies' we'll assume that you are happy to receive all cookies and you won't see this message again. If you click 'Reject all non-essential cookies' only necessary cookies providing core functionality such as security, network management, and accessibility will be enabled. Click 'Find out more' for information on how to change your cookie settings.

Researchers use data from primary care to identify a combination of routine blood tests that can aid earlier detection of this rare blood cancer.

In the UK, myeloma incidence has increased by 30% since the 1990s and 5700 cases of myeloma are diagnosed every year. However, possibly because the symptoms are non-specific, patients with myeloma have the longest intervals from initial symptom reporting to diagnosis of all common cancers, with the most consultations in primary care before referral.

Researchers at Oxford University, the University of Exeter and Chiddenbrook Surgery, Crediton have collaborated to try to improve myeloma diagnosis. Using a case-control study of 2,703 myeloma cases and 12,157 matched controls, they investigated how useful a number of different routine blood-based measures were for indicating the presence of the disease. Their work, published in the British Journal of General Practice, demonstrated that a simple combination of two blood parameters – plasma viscosity or erythrocyte sedimentation rate and haemoglobin levels - could be sufficient to diagnose patients.

Dr Brian D Nicholson, clinical researcher at the Nuffield Department of Primary Care in Oxford, and co-author of the study stated: “We wanted to develop a simple rule based on existing commonly used blood tests to help GPs identify which patients should be investigated further for Myeloma. By achieving this we offer guidance that can be implemented immediately in routine primary care to benefit all patients.

Constantinos Koshiaris, lead author of the study, from Oxford University, said: “The combination of levels of haemoglobin, the oxygen carrier in the blood, and one of two inflammatory markers (erythrocyte sedimentation rate or plasma viscosity) are a sufficient test to rule out myeloma. If abnormalities are detected in this test, it should lead to urgent urine protein tests which can help speed up diagnosis.”

The authors also suggest the possibility of integrating a system in the electronic health record to alert clinicians to relevant symptoms or changes in blood parameters related to myeloma.

For more information, see the news story on the University of Oxford website.

This work is funded by the Primary Care Research Trust and:

University of Oxford logoNIHR Collaboration for Leadership in Applied Health Research and Care Oxford logo

Similar stories

Oxford Centre for Early Cancer Detection Symposium 2023 – a recap

On Tuesday 5th December, the Oxford early cancer detection community gathered at the Mathematical Institute in Oxford to hear some highlights from OxCODE’s research in the past year and to discuss ideas for future projects.